title: [Metabolic Control, Evaluation and Follow-up Interventions in Patients With Schizophrenia].
abstract: OBJECTIVE
  To determine the laboratory tests, related to metabolic risk that should be practiced to adult patients diagnosed with schizophrenia. To assist the clinician decision-making process about complementary diagnostic evaluation strategies in adult diagnosed with schizophrenia.
  
  
  METHODS
  A clinical practice guideline was elaborated under the parameters of the Methodological Guide of the Ministerio de Salud y Protección Social to identify, synthesize and evaluate the evidence and make recommendations about the treatment and follow-up of adult patients with schizophrenia. The evidence of NICE guide 82 was adopted and updated. The evidence was presented to the Guideline Developing Group and recommendations, employing the GRADE system, were produced.
  
  
  RESULTS
  The risk of overall mortality in schizophrenia is higher than in the general population excluding suicide. Results related with mortality associated to antipsychotics showed contradictory results. Metabolic outcomes showed a higher incidence and association with schizophrenia and treatment with antipsychotics (AP). The diagnosis of dyslipidemia in men with schizophrenia appears to be lower in comparison with the general population. However, changes in weight, blood sugar levels, HDL cholesterol and triglycerides are influenced by the use of antipsychotics in general there is a higher risk of developing diabetes mellitus in adults with schizophrenia.
  
  
  CONCLUSIONS
  Based on the evidence found a plan was formulated for the evaluation of physiological and paraclinical variables during and before the management with AP in adult diagnosed with schizophrenia. The overall quality of evidence is low considering that most of the reports come from observational studies that have risk of bias and some designs have methodological limitations.
authors.affiliation: Médico psiquiatra, subespecialista en psiquiatría de enlace, Profesor departamento de Psiquiatría y Salud Mental, Pontificia Universidad Javeriana. Hospital Universitario San Ignacio, Bogotá, Colombia. Delegado Asociación Colombiana de Psiquiatría. Electronic address: goviedo@javeriana.edu.co.
authors.forename: Gabriel Fernando
authors.initials: GF
authors.lastname: Oviedo
authors.affiliation: Médico psiquiatra, psicoanalista, psiquiatra de enlace, magíster en Epidemiología Clínica. Profesor titular y Director del Departamento de Epidemiología Clínica y Bioestadística. Pontificia Universidad Javeriana. Hospital Universitario San Ignacio, Bogotá, Colombia.
authors.forename: Carlos
authors.initials: C
authors.lastname: Gómez Restrepo
authors.affiliation: Médica psiquiatra, magístra en Epidemiología Clínica. Profesora asistente del departamento de Psiquiatría y Salud Mental. Pontificia Universidad Javeriana, Bogotá, Colombia.
authors.forename: Adriana
authors.initials: A
authors.lastname: Bohórquez Peñaranda
authors.affiliation: Médica psiquiatra, Doctora en Epidemiología Clínica. Profesora asociada del Departamento de Psiquiatría, Facultad de Medicina. Universidad de Antioquia, Medellín, Antioquia, Colombia.
authors.forename: Jenny
authors.initials: J
authors.lastname: García Valencia
authors.affiliation: Médico psiquiatra, Master en Farmacología. Profesor Universidad Nacional de Colombia, Bogotá, Colombia.
authors.forename: Luis Eduardo
authors.initials: LE
authors.lastname: Jaramillo
authors.affiliation: Médica psiquiatra, candidata a MSc Epidemiología Clínica. Pontificia Universidad, Bogotá, Colombia.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Tamayo
authors.affiliation: Médico, Residente de Psiquiatría General, Pontificia Universidad Javeriana. Asistente de investigación, Bogotá, Colombia.
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Arenas
authors.affiliation: Médica cirujana, Residente de Psiquiatría Pontificia Universidad Javeriana. Asistente de investigación, Bogotá, Colombia.
authors.forename: Carolina
authors.initials: C
authors.lastname: Vélez Fernández
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000066491:Clinical Decision-Making; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000209:etiology; D050171:Dyslipidemias / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008659:Metabolic Diseases / Q000453:epidemiology* / Q000209:etiology; D017410:Practice Guidelines as Topic; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000401:mortality
chemical_list: D014150:Antipsychotic Agents
keywords: Clinical Practice Guidelines; Esquizofrenia; Guía de práctica clínica; Metabolic risk; Schizophrenia; Síndrome metabólico